Titanox

Quick links to important sections

Titanox

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Titanox

Quick Facts about Titanox

Property Description
Active ingredient Mebendazole (INN)
Form Cream or Emulsion (Topical)
Pharmacological class Anthelmintic (Benzimidazole carbamate)
Common route of admin. Topical (Dermal)
Origin Synthetic Organic Chemistry

Titanox is a specialized topical pharmaceutical preparation containing the active ingredient Mebendazole, which is fundamentally a member of the benzimidazole carbamate drug class. This medication is distinct because it is formulated as a viscous cream or emulsion intended exclusively for dermal administration, focusing on localized treatment.

Unlike the more common oral forms of Mebendazole used for internal parasites, Titanox’s purpose is to deliver the active agent directly to the site of certain parasitic infestations affecting the skin. This approach allows for a high concentration of the drug at the infection site while minimizing systemic exposure.

The composition features Mebendazole (INN) alongside specialized excipients—such as emollients and stabilizers—that are crucial for ensuring the cream’s consistency and maximizing skin penetration. The Mebendazole component itself is clinically recognized globally, with the active ingredient being categorized as an essential medicine. Its classification as an anthelmintic reflects its targeted effect on parasitic organisms.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Titanox?

Possible Side Effects and Safety Information

The officially documented safety profile for the active ingredient Mebendazole is structured by regulatory bodies to communicate potential adverse reactions, their classification, and necessary safety constraints.

Adverse reactions are classified by both frequency and the specific system or organ they affect, as reported in regulatory documents. Commonly reported adverse reactions include gastrointestinal disorders such as abdominal pain, abdominal discomfort, diarrhea, and flatulence. Other effects are grouped into System-Organ Classes (SOCs) including Skin and Subcutaneous Tissue Disorders, Blood and Lymphatic System Disorders, and Nervous System Disorders.

Serious Adverse Reactions

The regulatory label explicitly lists rare, serious adverse events reported in postmarketing surveillance. These include severe skin reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as hematologic reactions such as Agranulocytosis and Neutropenia.

Population and Duration-Related Safety

Safety is not established for all patient groups; the official label notes that safety and effectiveness have not been established in infants below one year of age. The use of Mebendazole in pregnancy is noted as having inconclusive human data. Furthermore, hematologic effects like Neutropenia are associated with the use of higher dosages and prolonged durations of treatment.

Regulatory Constraints

The medication is contraindicated for individuals with known hypersensitivity to the active ingredient. A specific safety warning is documented regarding the concomitant use with Metronidazole, as this combination has been associated with reports of serious dermatologic reactions (SJS/TEN).

Overdose and Emergency Response

The official regulatory documentation for the active ingredient of Titanox addresses overdose primarily in scenarios involving exposure to dosages substantially higher than recommended or for prolonged periods of time. Accidental overdosage may initially present with non-specific gastrointestinal manifestations, including abdominal cramps, nausea, vomiting, and diarrhoea.

In documented severe or prolonged exposure contexts, the official prescribing information notes potential haematological disorders such as neutropenia and the more severe agranulocytosis. Hepatobiliary disturbances, including hepatitis and reversible liver function abnormalities, have been officially reported, along with renal findings like glomerulonephritis. The regulatory profile also explicitly notes that convulsions have occurred, specifically reported in infants below the age of one year.

Urgent medical attention must be sought immediately following any suspected overdosage or if severe symptoms develop. Management is centered on supportive and symptomatic care, as the official documentation states that no specific antidote is known for Mebendazole. Monitoring of blood counts and hepatic functions is generally advised for cases involving high-exposure or prolonged therapy.

Therapeutic Uses of Titanox

What Titanox Treats: Main Uses and Benefits

Titanox is commonly used for the therapeutic purpose of addressing the parasitic larvae that cause Cutaneous Larva Migrans (CLM), or creeping eruption. This condition is marked by the localized activity of hookworm larvae, resulting in pronounced symptoms. This class of medicine is generally recognized as relevant for managing parasitic infections, and may help support the management of the infection and contribute to supporting the symptomatic course of the skin disease.

The medication is relevant for easing challenging symptomatic phases, including intense, persistent itching (pruritus), the pronounced dermal inflammatory reaction, and symptoms that interfere with daily comfort, such as disruption of sleep patterns. The specialized topical approach is relevant in contexts involving acute symptomatic episodes, such as infestations acquired by travelers after environmental exposure in tropical regions. This supportive relief assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for CLM Symptoms
Symptom Category: Localized Skin Discomfort
Condition Context: Acute Dermatological Parasitosis
Primary Benefit: Supports easing of intense pruritus and skin inflammation
Real-World Use: Symptomatic management post-travel exposure

Regulatory References

  1. NIH MedlinePlus overview on Mebendazole

Eligibility and Restrictions for Use

Who can and cannot use Titanox?

The eligibility for Titanox is defined by regulatory documents based on absolute prohibitions and population-specific restrictions. Official labeling states the medicine is contraindicated in two key populations: patients with a known hypersensitivity or allergy to Mebendazole or any component of the cream, and infants below the age of 1 year due to the documented risk of convulsions reported with Mebendazole formulations.


Age-Group Eligibility

Age Group Official Regulatory Status
Infants (<1 year) Contraindicated
Children (1 to <2 years) Use Not Established (Use is restricted and requires professional risk assessment).
Children (≥2 years) & Adults Generally Eligible (provided no contraindications exist).
Geriatric Patients No information is available on the relationship of age to the drug’s effects.

Pregnancy and Conditional Use

Use is not recommended for pregnant women (classified as Pregnancy Category C), as the potential benefit must justify the possible risk. Nursing mothers should exercise caution, as it is not known whether the active ingredient is excreted in human milk. Additionally, the label requires professional attention and monitoring for patients with pre-existing hepatic (liver) disease or dysfunction.

What should I know about interactions with other medicines?

Titanox is the common designation for Titanium Dioxide (TiO₂) when used as an ingredient in medicinal products. It is officially classified as a pharmaceutical excipient (an inactive ingredient), not an active drug, and therefore, it does not have documented drug-drug interactions with other active pharmaceutical ingredients (APIs).

Regulatory Context and Constraints

Titanium dioxide’s interaction profile is defined by its critical technical role in the formulation of many medicines. Regulatory bodies, such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), confirm its function as a white pigment and opacifier in tablet coatings and capsule shells. This function is vital for the protection of light-sensitive APIs from degradation, which in turn maintains the quality, safety, and efficacy of the medicine throughout its shelf life. TiO₂ also ensures a consistent appearance for product identification.

Interaction-Related Status

The use of TiO₂ in medicines is subject to specific regulatory review, particularly in the European Union (EU), due to concerns raised about its safety as a food additive (E 171). However, based on scientific analysis, the regulatory consensus is that no simple, technically feasible alternatives are currently available to replace TiO₂ without risking significant medicine shortages or negatively impacting the quality and stability of thousands of essential products. Consequently, its use as an excipient in medicinal products is maintained under a special regulatory provision.

Mechanism of Action

Selective β-Tubulin Binding and Structural Collapse

Titanox acts at the molecular level by exhibiting high-affinity binding to the parasite's structural protein, β-Tubulin, selectively inhibiting its polymerization into microtubules. This mechanism fundamentally affects the organism's cellular framework, leading to the rapid and severe structural disruption of its intestinal and tegumentary cells.

Cascade of Energy Depletion and Immobilization

The primary structural damage initiates a critical functional cascade, causing a severe block in glucose uptake and subsequent rapid depletion of the organism's glycogen reserves. This metabolic failure combines with the inability to maintain cellular transport and motility, resulting in the functional failure and immobilization of the target organism.

Dosage and Administration Information

How Titanox Is Used

Titanox is a specialized topical preparation containing the anthelmintic agent Mebendazole, and its administration is defined by guidelines for dermal use. The official instructions mandate a precise regimen focused on localized application to treat conditions such as Cutaneous Larva Migrans (CLM).


Administration Overview

Entity Official Regulatory Pattern
Administration Route Dermal, Topical use only, applied directly to the skin.
Form and Dosing Applied as a cream or emulsion in a thin film sufficient to cover the entire affected area (the migratory tract).
Frequency The standard schedule is application twice daily, typically morning and evening, for a continuous course.
Duration Treatment is designed as a short course, usually lasting approximately 5 to 7 days, or until clinical resolution of symptoms.
Special Conditions Must be applied to clean, dry skin. Application must be restricted to the skin and must avoid contact with mucous membranes, including the eyes and mouth.

Official Usage Protocol

Official instructions establish a structured, non-systemic approach to using the medicine. The administration process is localized and defined by the following procedural steps, which ensure adherence to label guidelines:

  • The patient applies the cream or emulsion to a clean skin surface.
  • A thin layer of the product must be applied to cover the entire length of the visible lesion.
  • This process must be administered consistently twice daily over the defined duration.
  • Hands must be washed thoroughly immediately following the application process.

This protocol sets a rigid, standardized procedure for the twice-daily application of a non-volumetric dose over a finite treatment period, aligning its use with the expectations for localized antiparasitic therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research investigated the performance of the Titanium-Nitride-Oxide (TiNO)–coated stent (referred to as Titanox) in patients with acute coronary syndromes (ACS), including acute myocardial infarction (MI).

Research on Primary Indication

Studies focused on comparing the Titanox-coated stent against other established stents, such as paclitaxel-eluting stents (PES) and everolimus-eluting stents (EES). Randomized trials were conducted in patient populations presenting with ACS.

Outcome Measured Titanox vs. PES (2 Years) Titanox vs. EES (5 Years)
Major Adverse Cardiac Events (MACE) Lower rate reported for Titanox Not significantly different
Stent Thrombosis (ST) Significantly lower rate reported for Titanox Lower rate reported for Titanox
Cardiac Death Lower rate reported for Titanox Lower rate reported for Titanox
Target Lesion Revascularization (TLR) Similar rate reported Similar rate reported

Long-Term Follow-up and Safety

Long-term follow-up data from large randomized clinical trials, such as the TITAX-AMI and TIDES-ACS trials, were collected to evaluate clinical outcomes up to five years post-implantation.

In the TITAX-AMI trial, which compared Titanox to PES, analysis suggested that the implantation of a Titanox stent resulted in reported better clinical outcome compared with PES at the two-year and five-year marks. This observation was primarily driven by lower cumulative rates of MI and stent thrombosis in the Titanox group.

In comparisons against EES, one five-year randomized trial reported that the overall rate of major adverse cardiac events was not significantly different between the Titanox-coated stent and EES. However, some individual component endpoints, including MI and stent thrombosis, were reported less frequently in the Titanox group.

Frequently Asked Questions (FAQ)

Common questions about Titanox (FAQ)

Q: How long does it usually take to notice a change with Titanox?

A: Studies on the active ingredient, Mebendazole, provide information on how quickly the body processes the drug. Official documents indicate that the active ingredient is observed to reach its maximum measured concentration in the bloodstream approximately 2 to 4 hours after administration. This pharmacokinetic information describes the rate at which the body absorbs the medicine.


Q: Can I take Titanox if I'm already taking supplements?

A: Regulatory information advises that patients should inform their healthcare professional about all products they are taking. This includes prescription and non-prescription medicines, as well as any vitamins and nutritional supplements. This practice is consistent with regulatory guidance for complete disclosure of all concurrent product use.


Q: Are there specific food or drink items I should avoid while on Titanox?

A: Official sources indicate that specific food or drink items may interact with the active ingredient. For example, regulatory documentation advises avoiding grapefruit juice due to its potential to interfere with drug metabolism. Other sources advise avoiding alcohol during treatment due to potential interaction and increased risk of adverse effects.


Q: Is Titanox known to cause any long-term issues?

A: The regulatory label notes that certain serious adverse effects have been reported in regulatory data in association with prolonged treatment or the use of higher dosages of Mebendazole. These reported effects include agranulocytosis (a blood disorder), neutropenia, and disturbances in liver function.


Q: Is Titanox safe for older adults to use?

A: According to official regulatory documents, there is currently no specific information available regarding the relationship between age and the drug’s effects in geriatric patients. Eligibility is generally determined based on the absence of specific contraindications mentioned in the official label.


Q: Can Titanox affect my sleep schedule?

A: Post-marketing surveillance reports on the active ingredient mention rare cases of nervous system effects. These effects, such as dizziness and drowsiness, are listed in official documents. Such nervous system effects may potentially influence the sleep schedule.


Q: Does taking Titanox mean I can’t drink alcohol at all?

A: Regulatory information advises avoiding alcohol while undergoing treatment with the active ingredient. This is because alcohol use may increase the likelihood of adverse effects or potentially impact liver function. Avoiding alcohol is consistent with official guidance.


Q: How quickly does the active ingredient in Titanox leave the body?

A: Official pharmacokinetic data indicates that the active ingredient, Mebendazole, is poorly absorbed by the body. The majority of the medicine is rapidly metabolized by the liver. As a result, less than 10% of the dose typically enters the systemic circulation.


Q: Can Titanox be taken by people with kidney issues?

A: Post-marketing reports for the active ingredient include rare cases of glomerulonephritis, which is a disorder affecting the kidneys. This information is included in official adverse reaction summaries, particularly for patient awareness regarding existing kidney issues.


Q: What kind of studies have been done to confirm Titanox’s purpose?

A: Official research confirms the drug’s intended classification as an anthelmintic, a medicine targeted against parasitic worms. The purpose of Mebendazole is supported by clinical trials that assess its efficacy in treating various parasitic infections.


Q: Why are there warnings about driving or operating machinery while taking Titanox?

A: Official warnings about driving or operating machinery are sometimes related to potential side effects in the nervous system. Adverse reactions such as dizziness and drowsiness have been reported in post-marketing experience with the active ingredient.


Q: Do I need to change my diet while on Titanox?

A: Regulatory documentation notes that certain elements of a patient’s diet can influence how the drug is absorbed. Specifically, taking the active ingredient alongside a high-fat meal may lead to increased absorption of the drug.


Q: Is it normal to feel a bit nauseous when first starting Titanox?

A: Gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea are among the adverse reactions reported in official documents for the active ingredient. This information is based on clinical trials and post-marketing surveillance.


Q: Can Titanox affect the results of common lab tests?

A: The regulatory label advises that periodic assessment of various organ systems is recommended during prolonged therapy. This includes monitoring blood cell counts and liver function. This suggests that the medicine can potentially affect these particular laboratory results.


Q: What is the risk of having a serious interaction with Titanox?

A: Regulatory documents include a specific warning regarding a serious interaction risk with another medication. Patients are officially warned to avoid the concomitant use of the active ingredient with Metronidazole. This combination has been associated with reports of rare, serious skin reactions.


Q: What should I do if I forget to take my Titanox?

A: The established protocol for a missed dose describes taking it as soon as it is remembered, unless it is almost time for the next scheduled application, at which point the missed dose is to be skipped. This information is consistent with regulatory guidance for administration.


Q: Is Titanox habit-forming or addictive?

A: According to general drug safety profiles, the active ingredient Mebendazole is not generally associated with habit-forming tendencies. This information is consistent across regulatory documents and safety data.


Q: Will Titanox impact my ability to get pregnant?

A: Studies examining the drug's impact on fertility have been performed in animals. Regulatory documents report that Mebendazole, at doses comparable to the human dose, was found to have no effect upon fetuses and offspring in these studies.


Q: Is it okay to take Titanox with common pain relievers like ibuprofen?

A: While specific interaction studies with every pain reliever are not always detailed, some studies have found no known interaction with acetaminophen. Official guidance remains that informing a healthcare professional about all prescription and non-prescription medicines is recommended to prevent potential issues.


Q: Can children or teenagers use Titanox?

A: Official regulatory information provides specific eligibility guidelines by age group. The label lists eligibility and restrictions for infants below 1 year and children 1 to 2 years of age. Children 2 years and older are generally described as eligible provided no contraindications exist.


Q: Does Titanox interact with herbal teas or natural products?

A: Official regulatory documents and safety guidelines advise that a patient should inform their healthcare professional about all products they are consuming. This includes any vitamins, nutritional supplements, herbal teas, or natural products. This practice is consistent with regulatory guidance for complete disclosure of all concurrent product use.


Q: If I miss a dose, should I take two the next time?

A: The official protocol included in regulatory documents is clear on this matter. Patients are advised not to double doses or take extra medicine to make up for a missed application. Following the prescribed dosing schedule is essential.


Q: Is it necessary to have routine blood tests while on Titanox?

A: The regulatory label advises that the periodic assessment of organ systems is recommended when the medicine is used for prolonged periods or at higher dosages. This monitoring includes checking blood counts and liver function. These assessments are advised due to associated risks mentioned in the label.


Q: Is Titanox a newer drug, or has it been around for a while?

A: The active ingredient, Mebendazole, is listed as an Essential Medicine by the World Health Organization. This classification generally indicates that the medicine has long-standing clinical recognition and use. Its inclusion reflects its established role in global health.


Q: What are the potential mental or emotional side effects of Titanox?

A: Official post-marketing surveillance reports on the active ingredient mention rare cases of nervous system effects. These effects, such as convulsions and dizziness, are listed in regulatory documents for patient awareness regarding potential central nervous system effects.


Q: Is it safe to store Titanox in a pill box?

A: Regulatory documents recommend that the product be stored in its original container, ensuring the container remains tightly closed. This is required to protect the integrity of the medicine, particularly from light and moisture. A pill box may not meet these specific storage requirements for a cream or emulsion.

How should Titanox be stored and disposed of?

Storage and Protection Requirements

Official regulatory labeling for the active ingredient (Mebendazole) requires the product to be stored at Controlled Room Temperature, which is typically 20^circ to 25 C (68^circ to 77 F). The medicine must be kept from freezing to maintain its integrity.

  • Environment: Store away from direct light and moisture.
  • Packaging: Keep the product in the original container and ensure the container remains tightly closed.
  • Child Safety: All medication must be stored strictly out of the reach and sight of children.

Official Disposal Protocol

Unused or expired product should not be released into the environment or flushed down drains. Disposal must follow regulatory guidelines:

  1. Prioritize using a drug take-back program or collecting facility.
  2. If a take-back option is unavailable, the medicine may be mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed container, and disposed of in the household trash.
  3. Scratch out all personal information on the label before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Titanox found in:

A-Z Index: